// App-Quantinova.ai

276 : Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib.

Researchers

Presenter

  • Juan W. Valle

Principal Investigators

  • Kristen Bibeau

  • Yohan Cho

  • Haobo Ren

  • Luis Fliz

  • Christine Francis Lihou

  • Ghassan K. Abou-Alfa

Medical Centers

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Incyte Corporation, Wilmington, DE

  • Incyte Biosciences International Sàrl,Morges,Schweiz

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United Kingdom

  • United States

  • Switzerland

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02924376

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved